Crossmark

Survival and Surrogate Biomarkers in Interventional Oncology Trials: Pitfalls, Challenges, and Future Directions

Published Online: 2026-01-16

Authors

Gonzalez, Ana P.

Swersky, Adam

Salem, Riad https://orcid.org/0000-0001-9745-1825
License Information

Text and Data Mining valid from 2026-01-16

Version of Record valid from 2026-01-16
More Information

Article History

Received: 5 April 2025

Accepted: 12 November 2025

First Online: 16 January 2026

Declarations

:

: Riad Salem is a consultant for Boston Scientific, Astrazeneca, Genentech, Sirtex, Cook, Eisai, Bard and QED Therapeutics. Ana P. Gonzalez and Adam Swersky report no conflicts.

Document is current